Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 1.10
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
XBIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
178+154.76%Social Signal Score
Mentions (3)
- News (RSS)seekingalpha·just now·Positive
XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)
View source ↗ - Newsseekingalpha.com·4h ago·Positive
XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade) State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid sector-wide optimism. XBI has surged 34% since March, outperforming XLV and SPY, fueled by M&A activity and positive clinical trial catalysts. Despite high volatility and small-cap risk, XBI's under-20x earnings multiple and diversified holdings support a constructive outlook.
View source ↗ - News (RSS)fool·2d ago·Positive
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.
View source ↗